2024-04-10 19:32:53 ET
Summary
- Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions.
- Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024.
- SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation.
- SLDB's valuation appears undervalued relative to its peers, which is why I ultimately lean bullish post-PIPE investment.
Read the full article on Seeking Alpha
For further details see:
Buy Solid Biosciences: Unpacking Its Main Value Driver